Skip to content
Screener

Cumberland Pharmaceuticals CPIX Q3 2025 earnings

Reported November 4, 2025 · After market close

Revenue$8.3M
EPS-$0.06

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$8.5M
EPS estimate-$0.13

Financials

Q3 2025

Income statement

See full
Revenue$8.3M-8.7%
Gross profit$7.3M-5.9%
Operating income-$2.0M-16.0%
Net income-$1.9M-25.7%
EPS (diluted)-$0.13-18.2%

Balance sheet

See full
Cash & equivalents$15.2M-13.0%
Total debt$5.0M-7.3%
Total equity$26.1M+5.4%
Total assets$65.9M-14.1%

Cash flow

See full
Operating cash flow$187.2K—
CapEx$23.8K+54.7%
Free cash flow$163.4K—

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$46.68M+158%
Enterprise value$36.48M+508%
P/S1.5×+1.0×

Profitability

See full
Gross margin79.2%-4.1pp
Operating margin-18.3%-5.0pp
Net margin-10.8%-4.2pp

Returns & leverage

See full
Return on equity-13.1%-5.1pp
Debt / equity0.2×0.0×
Current ratio1.2×+0.1×

Segments

By product

See full
Sancuso$3.2M+24.3%
Vibativ$2.6M+153%
Other revenue$306.5K-50.9%

By geography

See full
Non-US$1.2M+81.5%

FAQ

When did Cumberland Pharmaceuticals report Q3 2025 earnings?
Cumberland Pharmaceuticals (CPIX) reported Q3 2025 earnings on November 4, 2025 after market close.
What were Cumberland Pharmaceuticals's Q3 2025 revenue and EPS?
Cumberland Pharmaceuticals reported revenue of $8.3M and eps of $-0.06 for Q3 2025.
How did Cumberland Pharmaceuticals's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 8.7% from $9.1M a year earlier and eps declined 200.0% from $-0.02.
Where can I find Cumberland Pharmaceuticals's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001087294-25-000017) and the 10-Q periodic report (0001087294-25-000020) directly on SEC EDGAR. The filing index links above go to sec.gov.